20/20 Onsite Tops 20+ CNS Trials, Driving Quality Ocular Endpoint Protection at Scale

BOSTON--(BUSINESS WIRE)--20/20 Onsite today announced it has supported 23 central nervous system (CNS)/neurology studies to date (including epilepsy, MDD, and bipolar disorder), including 10 studies in the last 10 months, with additional trials launching in the coming quarters. The milestone underscores growing sponsor demand for quality ocular endpoint protection delivered at the point of need, all backed by secure data workflows that streamline submissions and protect timelines.

Across its portfolio, 20/20 Onsite has achieved a 95+ patient Net Promoter Score (NPS), 100% screening timelines met, and 85,000+ ophthalmic assessments conducted across 48 states. In verified studies, the company has maintained ~91% patient retention versus an industry Phase 3 average near 70%, helping sponsors reduce re-visits, protect endpoints, and keep programs on schedule.

“CNS and neurology trials can live or die by the consistency and integrity of their ocular endpoints,” said Ivan Quiroz, VP, Clinic Operations, 20/20 Onsite. “Sponsors trust us because we bring certified teams, validated equipment, and a patient-first workflow directly to the point of need—sites, homes, or community locations—so they get high-quality data without adding burden to patients or sites. Our job is to get it done, and get it done right, every time.”

Purpose-Built to Protect Ocular Endpoints in Neuro Trials

20/20 Onsite’s model pairs field-based ophthalmic experts with validated imaging and exam equipment deployed via mobile vision clinics, mobile vision pods, and mobile clinic suites. This point-of-need approach reduces travel, improves consistency across timepoints, and increases access for underrepresented populations. These are key advantages for neurology programs where protocol adherence and patient experience directly influence data quality.

Outcomes Sponsors Can Measure

• 23 CNS/Neuro studies supported (10 in the last 10 months); additional programs in startup
• 95+ NPS from patients, reflecting high satisfaction and reduced burden
• 100% screening timelines met, enabling on-schedule enrollment and visits
• 85,000+ ophthalmic assessments completed across 48 states
• ~91% patient retention vs ~70% Phase 3 industry average, helping protect endpoints and reduce costly re-visits

“Every neuro sponsor we serve asks the same questions: Will our endpoints be protected, will our patients stay engaged, and will we hit our dates?” added Quiroz. “Our answer is operational: certified people, standardized workflows, validated equipment, and a delivery model that meets patients where they are. That’s how we keep trials moving.”

With more neurology studies in early trial phases, 20/20 Onsite continues to expand capacity and geographic coverage to help sponsors scale consistently — from single-site studies to multi-region programs — without sacrificing quality or speed.

About 20/20 Onsite
20/20 Onsite is a clinical trial solutions company specializing in quality ocular endpoint protection through its nationwide point-of-need fleet. By bringing advanced ophthalmic assessments directly to clinical trial participants—whether at sites, homes, or community locations—20/20 Onsite makes it easier for sponsors, CROs, and sites to collect critical data, reduce patient burden, and improve trial outcomes.

20/20 Onsite has supported over 40 clinical trials, served more than 85,000 patients, achieved 100% of screening timelines, and consistently delivered patient Net Promoter Scores (NPS) above 95.

To learn more about how 20/20 Onsite delivers quality ocular endpoint protection at scale, visit www.2020onsite.com.